In this issue of Current Oncology

In this issue of Current Oncology


M. McLean, MD

In women with early-stage breast cancer, the use of fec-d (5-fluorouracil–epirubicin–cyclophosphamide followed by docetaxel) has increased, given the increased efficacy of that regimen compared with fec-100 (5-fluorouracil–epirubicin–cyclophosphamide). The initial report of fec-d’s superiority was enhanced by the relatively low rate of neutropenic sepsis claimed. However, that low rate has been challenged in an excellent retrospective analysis by Husain et al., who report their “real world” experience in this issue. I am also indebted to Drs. Booth and Rapoport for their excellent guest editorial reviewing that analysis. The concerns of these authors and their reviewers hold lessons for us all.

Elsewhere in this issue, a report by Hagan et al. from the Tom Baker Cancer Centre evaluates tetrodotoxin in the management of chronic cancer pain. Although the authors recommend further evaluation, the initial impression from this experienced team is clearly encouraging.

The other excellent manuscripts in this issue—a most eclectic mix—are also sure to promote thought and reflection, perhaps none more so than the account of the life and times of Canada’s first true medical oncologist, Dr. O. Harold Warwick, a graduate of McGill in 1940 and subsequently a Rhodes Scholar. His practice spanned almost a half century, and his death in 2009 came only after a long and productive retirement. His experiences and achievements, as recounted by his biographer, Dr. Donald H. Cowan, make compelling reading for all—but perhaps in particular for those entering this specialty, which continues to evolve at a rapid rate. Dr. Warwick was a true Canadian pioneer.


(Return to Top)



Current Oncology, VOLUME 18, NUMBER 3, 2011








Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)